clinical trial · NCT06053814
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NS Pharma, Inc.·phase2·active not recruiting·n = 20
Duchenne Muscular DystrophyNS-050/NCNP-03Placebo
brief summary
This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.
started
Sep 18, 2024
primary completion
May 1, 2027
completion
Mar 1, 2028
last updated
Apr 23, 2026
official title
A Phase 1/2, First in Human, Multiple-dose, 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-050/NCNP-03 in Boys With Duchenne Muscular Dystrophy (DMD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol